Jeet Mukherjee
Stock Analyst at BTIG
(3.02)
# 1,411
Out of 5,182 analysts
41
Total ratings
41.46%
Success rate
2.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Reiterates: Buy | $48 | $27.32 | +75.70% | 2 | Mar 26, 2026 | |
| AARD Aardvark Therapeutics | Reiterates: Buy | $9 | $4.30 | +109.30% | 4 | Mar 24, 2026 | |
| ARVN Arvinas | Maintains: Buy | $14 → $16 | $10.85 | +47.47% | 3 | Mar 19, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $4.41 | +217.46% | 4 | Mar 17, 2026 | |
| VSTM Verastem | Assumes: Buy | $19 | $5.63 | +237.48% | 1 | Mar 12, 2026 | |
| IPHA Innate Pharma | Assumes: Buy | $8 | $1.39 | +475.54% | 1 | Mar 12, 2026 | |
| IBRX ImmunityBio | Assumes: Buy | $13 | $7.30 | +78.08% | 1 | Mar 12, 2026 | |
| AVBP ArriVent BioPharma | Assumes: Buy | $42 | $24.89 | +68.74% | 1 | Mar 12, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $138 → $134 | $85.40 | +56.91% | 6 | Feb 26, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $192 → $215 | $123.46 | +74.15% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $104 | $55.13 | +88.65% | 6 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $15.51 | +93.42% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $21.47 | +30.41% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.93 | +123.12% | 1 | Dec 18, 2025 |
Ascentage Pharma Group International
Mar 26, 2026
Reiterates: Buy
Price Target: $48
Current: $27.32
Upside: +75.70%
Aardvark Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $9
Current: $4.30
Upside: +109.30%
Arvinas
Mar 19, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $10.85
Upside: +47.47%
Perspective Therapeutics
Mar 17, 2026
Reiterates: Buy
Price Target: $14
Current: $4.41
Upside: +217.46%
Verastem
Mar 12, 2026
Assumes: Buy
Price Target: $19
Current: $5.63
Upside: +237.48%
Innate Pharma
Mar 12, 2026
Assumes: Buy
Price Target: $8
Current: $1.39
Upside: +475.54%
ImmunityBio
Mar 12, 2026
Assumes: Buy
Price Target: $13
Current: $7.30
Upside: +78.08%
ArriVent BioPharma
Mar 12, 2026
Assumes: Buy
Price Target: $42
Current: $24.89
Upside: +68.74%
Kymera Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $138 → $134
Current: $85.40
Upside: +56.91%
Palvella Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $192 → $215
Current: $123.46
Upside: +74.15%
Feb 23, 2026
Reiterates: Buy
Price Target: $104
Current: $55.13
Upside: +88.65%
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $15.51
Upside: +93.42%
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $21.47
Upside: +30.41%
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $4.93
Upside: +123.12%